Online inquiry

IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5124MR)

This product GTTS-WQ5124MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL1RAP gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001167928.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3556
UniProt ID Q9NPH3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5124MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4975MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA c2G4-N
GTTS-WQ10525MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY-3015014
GTTS-WQ7026MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Fab C225
GTTS-WQ15692MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ14320MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RG7414
GTTS-WQ9031MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ3342MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AT-001
GTTS-WQ6948MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ESBA-1008
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW